Outlook Therapeutics (OTLK) News Today → Trump’s Gift Could Unleash $51 Billion in New Wealth (From Wealthpin Pro) (Ad) Free OTLK Stock Alerts $7.07 -0.15 (-2.08%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 2 at 3:42 AM | americanbankingnews.comOutlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Consensus Rating of "Moderate Buy" from AnalystsJune 2 at 3:41 AM | marketbeat.comOutlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Average Rating of "Moderate Buy" from AnalystsShares of Outlook Therapeutics, Inc. (NASDAQ:OTLK - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the eight research firms that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and seven have isMay 29, 2024 | finance.yahoo.comGlobal Sustainable Aviation Fuel (SAF) Market Outlook 2030 with Neste, World Energy, Gevo, Aemetis, and SkyNRG Dominating the $25 Billion IndustryMay 29, 2024 | markets.businessinsider.comBuy Rating Justified by Outlook Therapeutics’ Advancements and Market ProspectsMay 28, 2024 | msn.comOutlook gets EU approval for Lytenava for wet AMDMay 28, 2024 | globenewswire.comOutlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMDMay 23, 2024 | americanbankingnews.comResearch Analysts Offer Predictions for Outlook Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:OTLK)May 22, 2024 | marketbeat.comChardan Capital Weighs in on Outlook Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:OTLK)Outlook Therapeutics, Inc. (NASDAQ:OTLK - Free Report) - Equities researchers at Chardan Capital reduced their FY2024 earnings estimates for shares of Outlook Therapeutics in a research report issued on Sunday, May 19th. Chardan Capital analyst D. Gataulin now forecasts that the company will earnMay 17, 2024 | markets.businessinsider.comBuy Rating Affirmed for Outlook Therapeutics on Strong EU Prospects and Solid Financial PositionMay 17, 2024 | marketbeat.comOutlook Therapeutics (NASDAQ:OTLK) Given "Buy" Rating at HC WainwrightHC Wainwright reissued a "buy" rating and set a $30.00 price objective on shares of Outlook Therapeutics in a report on Friday.May 17, 2024 | msn.comOutlook Therapeutics, Inc. (NASDAQ:OTLK) Q2 2024 Earnings Call TranscriptMay 17, 2024 | finance.yahoo.comQ2 2024 Outlook Therapeutics Inc Earnings CallMay 15, 2024 | globenewswire.comOutlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate UpdateMay 13, 2024 | globenewswire.comOutlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMDMay 10, 2024 | marketbeat.comOutlook Therapeutics (OTLK) to Release Quarterly Earnings on ThursdayOutlook Therapeutics (NASDAQ:OTLK) will be releasing earnings before the market opens on Thursday, May 16, Zacks reports.May 9, 2024 | finance.yahoo.comOutlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and WebcastMay 9, 2024 | globenewswire.comOutlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and WebcastMay 3, 2024 | finance.yahoo.comGlobal $320 Billion Aviation Fuel Market Outlook, 2024-2029: Emission Reduction Initiatives, Rising Air Freight Demand, Emerging MarketsMay 3, 2024 | msn.comHow to fix Microsoft OutlookMay 2, 2024 | globenewswire.comOutlook Therapeutics® to Present at the Retina World Congress 2024April 29, 2024 | globenewswire.comOutlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation ShowcaseApril 29, 2024 | msn.comThese 5 programs are way better than Microsoft OutlookApril 29, 2024 | usnews.comHCLTech Falls Most in Nearly 17 Months on Lower-Than-Expected FY25 OutlookApril 29, 2024 | finance.yahoo.comBest's Market Segment Report: AM Best Maintains Stable Outlook on Insurance Markets of Gulf Cooperation CouncilApril 26, 2024 | finance.yahoo.comGlobal Aluminum Wire with a Focus on Aerospace Market Outlook 2023-2036April 26, 2024 | msn.comHow to Use Copilot in OutlookApril 22, 2024 | finance.yahoo.comBest's Market Segment Report: AM Best Revises Outlook on London Market Insurance Segment to PositiveApril 22, 2024 | markets.businessinsider.comWGA Releases New Housing Finance OutlookApril 22, 2024 | msn.comOutlook: How to set up breaks between your meetingsApril 21, 2024 | finance.yahoo.comOutlook Therapeutics, Inc. (OTLK)April 18, 2024 | finance.yahoo.comWorld Polyethylene High Density (HDPE) Market Outlook 2024-2033: Capacities, Production, Consumption, Trade Statistics, and PricesApril 18, 2024 | usnews.comBosch Flags Further Cost Cuts After Giving 'Subdued' Outlook for 2024April 15, 2024 | globenewswire.comOutlook Therapeutics® Announces Closing of Private Placement of $5.0 MillionApril 15, 2024 | investorplace.comBiotech on a Budget: 7 Stocks Under $10 With Huge PotentialApril 14, 2024 | msn.comUS Consumer Sentiment Falls Slightly as Outlook for Inflation WorsensApril 14, 2024 | msn.comMicrosoft Outlook 2010's Default Profile Pic Was Based on Bill Gates' 1977 Mug Shot?April 11, 2024 | fxstreet.comFed's Williams: Outlook is uncertain, Fed must be data-dependentApril 11, 2024 | msn.comStock Market Today: Wall Street Falls After Hot Inflation Data Burns Hopes for a June Rate CutApril 11, 2024 | msn.comBitdefender now has identity protection for Gmail and OutlookApril 10, 2024 | finance.yahoo.comInsiders are Piling into These 10 Healthcare Stocks in 2024April 3, 2024 | forbes.comUsers Complain Gmail Blocks Email From Microsoft Outlook—Here’s The FixApril 3, 2024 | msn.comOutlook.com trips over Google's spam blocking rulesMarch 30, 2024 | insidertrades.comYezan Munther Haddadin Purchases 1,882 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) StockMarch 29, 2024 | uk.investing.comBTIG upgrades Outlook Therapeutics stock to buy, cites ONS-5010 successMarch 29, 2024 | marketbeat.comOutlook Therapeutics, Inc. (NASDAQ:OTLK) Director Yezan Munther Haddadin Acquires 1,882 SharesOutlook Therapeutics, Inc. (NASDAQ:OTLK - Get Free Report) Director Yezan Munther Haddadin acquired 1,882 shares of Outlook Therapeutics stock in a transaction that occurred on Thursday, March 28th. The shares were purchased at an average cost of $11.82 per share, for a total transaction of $22,245.24. Following the purchase, the director now directly owns 5,049 shares of the company's stock, valued at approximately $59,679.18. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.March 27, 2024 | marketbeat.comOutlook Therapeutics, Inc. (NASDAQ:OTLK) Short Interest Down 93.3% in MarchOutlook Therapeutics, Inc. (NASDAQ:OTLK - Get Free Report) saw a large drop in short interest in March. As of March 15th, there was short interest totalling 785,300 shares, a drop of 93.3% from the February 29th total of 11,640,000 shares. Approximately 10.6% of the company's stock are short sold. Based on an average trading volume of 496,200 shares, the days-to-cover ratio is currently 1.6 days.March 27, 2024 | markets.businessinsider.comBuy Rating for Outlook Therapeutics: Promising FDA Developments and Strong Financial Position Support $50 Price TargetMarch 27, 2024 | msn.comOutlook Therapeutics shares rise after 'buy' rating from BTIGMarch 27, 2024 | marketbeat.comOutlook Therapeutics (NASDAQ:OTLK) Upgraded by BTIG Research to BuyBTIG Research raised Outlook Therapeutics from a "neutral" rating to a "buy" rating and set a $50.00 price objective for the company in a report on Wednesday.March 25, 2024 | markets.businessinsider.comOutlook Therapeutics: Buy Rating Affirmed Amid Positive European Developments and Anticipated U.S. Market Success Get Outlook Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OTLK and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s Gift Could Unleash $51 Billion in New Wealth (Ad)In January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house republicans called “The Key To America’s Economic Future”. You just have to make this simple move before July 30, 2024. OTLK Media Mentions By Week OTLK Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OTLK News Sentiment▼0.400.76▲Average Medical News Sentiment OTLK News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OTLK Articles This Week▼54▲OTLK Articles Average Week Get Outlook Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OTLK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Athira Pharma News Today bluebird bio News Today BioAtla News Today AlloVir News Today Precision BioSciences News Today Gritstone bio News Today Protalix BioTherapeutics News Today Cognition Therapeutics News Today Omega Therapeutics News Today DBV Technologies News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OTLK) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersBiden Nomination CANCELED?The Freeport SocietyWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Outlook Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
